Cost-effectiveness of sustained-release morphine for refractory breathlessness in COPD: A randomized clinical trial

  • Cornelia A. Verberkt
    Affiliations
    Department of Health Services Research, Care and Public Health Research Institute, Faculty of Health Medicine and Life Sciences, Maastricht University, P.O. Box 616, 6200MD, Maastricht, the Netherlands
    Search for articles by this author
  • Marieke H.J. van den Beuken-van Everdingen
    Affiliations
    Centre of Expertise for Palliative Care, Maastricht University Medical Centre (MUMC+), P.O. Box 5800, 6202AZ, Maastricht, the Netherlands
    Search for articles by this author
  • Carmen D. Dirksen
    Affiliations
    Department of Clinical Epidemiology and Medical Technology Assessment, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Center, P.O. Box 5800, 6202AZ, Maastricht, the Netherlands
    Search for articles by this author
  • Jos M.G.A. Schols
    Affiliations
    Department of Health Services Research, Care and Public Health Research Institute, Faculty of Health Medicine and Life Sciences, Maastricht University, P.O. Box 616, 6200MD, Maastricht, the Netherlands

    Department of Family Medicine, Care and Public Health Research Institute, P.O. Box 616, 6200MD, Maastricht University, Maastricht, the Netherlands
    Search for articles by this author
  • Emiel F.M. Wouters
    Affiliations
    Department of Research & Development, Ciro, P.O. Box 4009, 6080AA, Haelen, the Netherlands

    Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), P.O. Box 5800, 6202AZ, Maastricht, the Netherlands

    Ludwig Boltzmann Institute for Lung Health, Vienna, Austria
    Search for articles by this author
  • Daisy J.A. Janssen
    Correspondence
    Corresponding author. Department of Research & Development, Ciro, P.O. Box 4009, 6080AA, Haelen, the Netherlands.
    Affiliations
    Department of Health Services Research, Care and Public Health Research Institute, Faculty of Health Medicine and Life Sciences, Maastricht University, P.O. Box 616, 6200MD, Maastricht, the Netherlands

    Department of Research & Development, Ciro, P.O. Box 4009, 6080AA, Haelen, the Netherlands
    Search for articles by this author
Published:February 09, 2021DOI:https://doi.org/10.1016/j.rmed.2021.106330

      Highlights

      • Regular, low-dose, oral morphine improves health-related quality of life in COPD.
      • Healthcare and societal costs are improved after four weeks of morphine.
      • Therefore, regular, low-dose, oral morphine can be considered cost-effective.
      • Morphine should be considered in patients with COPD and chronic breathlessness.

      Abstract

      Background

      Chronic breathlessness is a frequent symptom in advanced Chronic Obstructive Pulmonary Disease (COPD) and has major impact on quality of life, daily activities and healthcare utilization. Morphine is used as palliative treatment of chronic breathlessness. The aim is to analyze cost-effectiveness of regular, low-dose morphine in patients with advanced COPD from a healthcare and societal perspective.

      Methods

      In a randomized controlled trial, participants with advanced COPD were assigned to 10 mg regular, oral sustained-release morphine or placebo twice daily for four weeks. Quality of life (COPD Assessment Test; CAT), quality-adjusted life years (QALY's; EQ-5D-5L), healthcare costs, productivity, and patient and family costs were collected. Incremental cost-effectivity ratio's (ICERs) using healthcare costs and CAT scores, and incremental cost-utility ratio's (ICURs) using societal costs and QALY's were calculated.

      Results

      Data of 106 of 124 participants were analyzed, of which 50 were in the morphine group (mean [SD] age 65.4 [8.0] years; 58 [55%] male). Both ICER and ICUR indicated dominance for morphine treatment. Sensitivity analyses substantiated these results. From a healthcare perspective, the probability that morphine is cost-effective at a willingness to pay €8000 for an minimal clinically important difference of 2 points increase in CAT score is 63%. From a societal perspective, the probability that morphine is cost-effective at a willingness to pay €20,000 per QALY is 78%.

      Conclusion

      Morphine for four weeks is cost-effective regarding the healthcare and the societal perspective. To estimate the long-term costs and effects of morphine treatment, a study of longer follow-up should be performed.

      Trial registration

      ClinicalTrials.gov (NCT02429050).

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Respiratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Janssen D.J.
        • Spruit M.A.
        • Uszko-Lencer N.H.
        • Schols J.M.
        • Wouters E.F.
        Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure.
        J. Palliat. Med. 2011; 14: 735-743
        • Global Initiative for Chronic Obstructive Lung Disease (Gold)
        Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 Report).
        2020
      1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
        Lancet. 2018; 392: 1789-1858
        • Johnson M.J.
        • Yorke J.
        • Hansen-Flaschen J.
        • Lansing R.
        • Ekstrom M.
        • Similowski T.
        • Currow D.C.
        Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness.
        Eur. Respir. J. 2017; 49
        • Gysels M.H.
        • Higginson I.J.
        The lived experience of breathlessness and its implications for care: a qualitative comparison in cancer, COPD, heart failure and MND.
        BMC Palliat. Care. 2011; 10: 15
        • Currow D.C.
        • Dal Grande E.
        • Ferreira D.
        • Johnson M.J.
        • McCaffrey N.
        • Ekström M.
        Chronic breathlessness associated with poorer physical and mental health-related quality of life (SF-12) across all adult age groups.
        Thorax. 2017; 72: 1151-1153
        • Smith A.K.
        • Currow D.C.
        • Abernethy A.P.
        • Johnson M.J.
        • Miao Y.
        • Boscardin W.J.
        • Ritchie C.S.
        Prevalence and outcomes of breathlessness in older adults: a national population study.
        J. Am. Geriatr. Soc. 2016; 64: 2035-2041
        • Solano J.P.
        • Gomes B.
        • Higginson I.J.
        A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease.
        J. Pain Symptom Manag. 2006; 31: 58-69
        • Dzingina M.D.
        • Reilly C.C.
        • Bausewein C.
        • Jolley C.J.
        • Moxham J.
        • McCrone P.
        • Higginson I.J.
        • Yi D.
        Variations in the cost of formal and informal health care for patients with advanced chronic disease and refractory breathlessness: a cross-sectional secondary analysis.
        Palliat. Med. 2017; 31: 369-377
        • Kirsch F.
        • Schramm A.
        • Schwarzkopf L.
        • Lutter J.I.
        • Szentes B.
        • Huber M.
        • Leidl R.
        Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study.
        Respir. Res. 2019; 20 (215-215)
        • Wouters E.F.
        Economic analysis of the Confronting COPD survey: an overview of results.
        Respir. Med. 2003; 97: S3-S14
        • Stephenson J.J.
        • Wertz D.
        • Gu T.
        • Patel J.
        • Dalal A.A.
        Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting.
        Int. J. Chronic Obstr. Pulm. Dis. 2017; 12: 1947-1959
        • Verberkt C.A.
        • van den Beuken-van Everdingen M.H.J.
        • Dirksen C.D.
        • Schols J.M.G.A.
        • Vanfleteren L.E.G.W.
        • Franssen F.M.E.
        • Groenen M.T.J.
        • Wouters E.F.M.
        • Janssen D.J.A.
        Healthcare and Societal Costs in Patients with COPD and Breathlessness after Completion of a Comprehensive Rehabilitation Program.
        COPD, Forthcoming2021
        • van Boven J.F.M.
        • Vegter S.
        • van der Molen T.
        • Postma M.J.
        COPD in the working age population: the economic impact on both patients and government.
        COPD. 2013; 10: 629-639
        • Ekstrom M.
        • Bajwah S.
        • Bland J.M.
        • Currow D.C.
        • Hussain J.
        • Johnson M.J.
        One evidence base; three stories: do opioids relieve chronic breathlessness?.
        Thorax. 2018; 73: 88-90
        • Barnes H.
        • McDonald J.
        • Smallwood N.
        • Manser R.
        Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness.
        Cochrane Database Syst. Rev. 2016; 3: Cd011008
        • Ekstrom M.
        • Nilsson F.
        • Abernethy A.A.
        • Currow D.C.
        Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review.
        Ann Am Thorac Soc. 2015; 12: 1079-1092
        • Abernethy A.P.
        • Currow D.C.
        • Frith P.
        • Fazekas B.S.
        • McHugh A.
        • Bui C.
        Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea.
        BMJ. 2003; 327: 523-528
        • Eiser N.
        • Denman W.T.
        • West C.
        • Luce P.
        Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome.
        Eur. Respir. J. 1991; 4: 926-931
        • Oxberry S.G.
        • Torgerson D.J.
        • Bland J.M.
        • Clark A.L.
        • Cleland J.G.
        • Johnson M.J.
        Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial.
        Eur. J. Heart Fail. 2011; 13: 1006-1012
        • Shohrati M.
        • Ghanei M.
        • Harandi A.A.
        • Foroghi S.
        • Harandi A.A.
        Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: a double-blind randomized clinical trial study.
        Pulm Med. 2012; 2012 (2012): 610921
        • Poole P.J.
        • Veale A.G.
        • Black P.N.
        The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease.
        Am. J. Respir. Crit. Care Med. 1998; 157: 1877-1880
        • Currow D.
        • Louw S.
        • McCloud P.
        • Fazekas B.
        • Plummer J.
        • McDonald C.F.
        • Agar M.
        • Clark K.
        • McCaffery N.
        • Ekstrom M.P.
        Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial.
        Thorax. 2020; 75: 50-56
        • Lanken P.N.
        • Terry P.B.
        • Delisser H.M.
        • Fahy B.F.
        • Hansen-Flaschen J.
        • Heffner J.E.
        • Levy M.
        • Mularski R.A.
        • Osborne M.L.
        • Prendergast T.J.
        • Rocker G.
        • Sibbald W.J.
        • Wilfond B.
        • Yankaskas J.R.
        • A.T.S.E.-o.-L.C.T. Force
        An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses.
        Am. J. Respir. Crit. Care Med. 2008; 177: 912-927
        • Mahler D.A.
        • Selecky P.A.
        • Harrod C.G.
        • Benditt J.O.
        • Carrieri-Kohlman V.
        • Curtis J.R.
        • Manning H.L.
        • Mularski R.A.
        • Varkey B.
        • Campbell M.
        • Carter E.R.
        • Chiong J.R.
        • Ely E.W.
        • Hansen-Flaschen J.
        • O'Donnell D.E.
        • Waller A.
        American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease.
        Chest. 2010; 137: 674-691
        • Integraal Kankercentrum Nederland
        Dyspneu in de palliatieve fase.
        2015
        • Verberkt C.A.
        • van den Beuken-van Everdingen M.H.
        • Franssen F.M.
        • Dirksen C.D.
        • Schols J.M.
        • Wouters E.F.
        • Janssen D.J.
        A randomized controlled trial on the benefits and respiratory adverse effects of morphine for refractory dyspnea in patients with COPD: protocol of the MORDYC study.
        Contemp. Clin. Trials. 2016; 47: 228-234
        • Verberkt C.A.
        • van den Beuken-van Everdingen M.H.J.
        • Schols J.
        • Hameleers N.
        • Wouters E.F.M.
        • Janssen D.J.A.
        Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial.
        JAMA Intern Med. 2020; 180: 1306-1314
        • Bestall J.C.
        • Paul E.A.
        • Garrod R.
        • Garnham R.
        • Jones P.W.
        • Wedzicha J.A.
        Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.
        Thorax. 1999; 54: 581-586
        • Johnson M.J.
        • Bland J.M.
        • Oxberry S.G.
        • Abernethy A.P.
        • Currow D.C.
        Clinically important differences in the intensity of chronic refractory breathlessness.
        J. Pain Symptom Manag. 2013; 46: 957-963
        • Currow D.C.
        • McDonald C.
        • Oaten S.
        • Kenny B.
        • Allcroft P.
        • Frith P.
        • Briffa M.
        • Johnson M.J.
        • Abernethy A.P.
        Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study.
        J. Pain Symptom Manag. 2011; 42: 388-399
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J. Chron. Dis. 1987; 40: 373-383
        • Holland A.E.
        • Spruit M.A.
        • Troosters T.
        • Puhan M.A.
        • Pepin V.
        • Saey D.
        • McCormack M.C.
        • Carlin B.W.
        • Sciurba F.C.
        • Pitta F.
        • Wanger J.
        • MacIntyre N.
        • Kaminsky D.A.
        • Culver B.H.
        • Revill S.M.
        • Hernandes N.A.
        • Andrianopoulos V.
        • Camillo C.A.
        • Mitchell K.E.
        • Lee A.L.
        • Hill C.J.
        • Singh S.J.
        An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease.
        Eur. Respir. J. 2014; 44: 1428-1446
        • Dodd J.W.
        • Hogg L.
        • Nolan J.
        • Jefford H.
        • Grant A.
        • Lord V.M.
        • Falzon C.
        • Garrod R.
        • Lee C.
        • Polkey M.I.
        • Jones P.W.
        • Man W.D.
        • Hopkinson N.S.
        The COPD assessment test (CAT): response to pulmonary rehabilitation.
        A multicentre, prospective study, Thorax. 2011; 66: 425-429
        • Jones P.W.
        • Harding G.
        • Berry P.
        • Wiklund I.
        • Chen W.H.
        • Kline Leidy N.
        Development and first validation of the COPD assessment test.
        Eur. Respir. J. 2009; 34: 648-654
        • Lin F.J.
        • Pickard A.S.
        • Krishnan J.A.
        • Joo M.J.
        • Au D.H.
        • Carson S.S.
        • Gillespie S.
        • Henderson A.G.
        • Lindenauer P.K.
        • McBurnie M.A.
        • Mularski R.A.
        • Naureckas E.T.
        • Vollmer W.M.
        • Lee T.A.
        • Consortium C.
        Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form.
        BMC Med. Res. Methodol. 2014; 14: 78
        • EuroQoL Group
        EuroQol-a new facility for the measurement of health-related quality of life.
        Health Pol. 1990; 16: 199-208
        • Versteegh M.M.
        • Vermeulen K.M.
        • Evers S.M.A.A.
        • de Wit G.A.
        • Prenger R.
        • Stolk E.A.
        Dutch tariff for the five-level version of EQ-5D.
        Value Health. 2016; 19: 343-352
        • EuroQoL Group
        Dutch EQ-5D-5L Crosswalk Value Set.
        2012
        • Nederland Zorginstituut
        Kostenhandleiding: methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg.
        2015
        • Nederlandse Zorg Autoriteit
        Tarievenlijst Eerstelijnsdiagnostiek.
        2013
        • Nederlandse Zorg Autoriteit
        Prestatie- en tariefbeschikking huisartsenzorg en multidisciplinaire zorg.
        2019
        • Nederland Zorginstituut
        Medicijnkosten.nl.
        https://www.medicijnkosten.nl/
        Date accessed: July 1, 2019
        • Nederland Zorginstituut
        Medicine and Medical Devices (GIP) Database.
        https://www.gipdatabank.nl/
        Date accessed: June 1, 2020
        • Drummond M.F.
        • Sculpher M.J.
        • Claxton K.
        • Stoddart G.L.
        • Torrance G.W.
        Methods for the Economic Evaluation of Health Care Programmes.
        Oxford University Press, 2015
        • Council for Public Health and Health Care
        Sensible and Sustainable Care (In Dutch).
        Zoetermeer, 2006
        • Kochovska S.
        • Huang C.
        • Johnson M.J.
        • Agar M.R.
        • Fallon M.T.
        • Kaasa S.
        • Hussain J.A.
        • Portenoy R.K.
        • Higginson I.J.
        • Currow D.C.
        Intention-to-Treat analyses for randomized controlled trials in hospice/palliative care: the case for analyses to be of people exposed to the intervention.
        J. Pain Symptom Manag. 2020; 59: 637-645
        • Smid D.E.
        • Franssen F.M.
        • Houben-Wilke S.
        • Vanfleteren L.E.
        • Janssen D.J.
        • Wouters E.F.
        • Spruit M.A.
        Responsiveness and MCID estimates for CAT, CCQ, and HADS in patients with COPD undergoing pulmonary rehabilitation: a prospective analysis.
        J. Am. Med. Dir. Assoc. 2017; 18: 53-58
        • IKNL/Palliactief
        Kwaliteitskader Palliatieve Zorg Nederland.
        2017
        • Krol M.
        • Brouwer W.
        How to estimate productivity costs in economic evaluations.
        Pharmacoeconomics. 2014; 32: 335-344
        • van den Hout W.B.
        The value of productivity: human-capital versus friction-cost method.
        Ann. Rheum. Dis. 2010; 69: i89-91